Barclays 28th Annual Global Healthcare Conference March 12, 2026 8:30 AM EDTCompany ParticipantsAmy Parison - Senior VP ...
Lipid-lowering therapy can be considered with a 10-year PREVENT-ASCVD risk estimate of 3% to <5% (borderline) and should be considered for those at 5% to <10% (intermediate) 10-year risk. For ...
Drug-resistant epilepsy affects millions worldwide, with focal cortical dysplasia (FCD) as one of the leading causes. Yet its ...
BACKGROUND: Aortic valve calcification increases leaflet stiffness and contributes to the development of calcific aortic valve disease. The molecular and cellular mechanisms underlying calcification ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results